Report
Mathijs Geerts Danau

mdxhealth FIRST LOOK: FY25 highlights show revenue in line with guidance

Mdxhealth provides insights into key FY25 parameters, with preliminary revenue landing at $ 109m (VA CSS: $ 108.5m) and YE cash at $ 29m (VA CSS: $ 34.5m). Revenue guidance for FY26 is set at a narrow yet ambitious range of $ 137-140m, implying a 26-28% y/y increase. Additionally, mdxhealth managed to amend the Exact Sciences payouts to be more back-end loaded bringing some ease to the cash position. We believe that mdxhealth is well-positioned for growth in 2026 now that the commercial engine is firing on all cylinders, hence we maintain our $ 4.2 TP and Buy rating.
Underlying
MDXHEALTH

Provider
KBC Securities
KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

 

Analysts
Mathijs Geerts Danau

Other Reports on these Companies
Other Reports from KBC Securities
Guy Sips ... (+7)
  • Guy Sips
  • Hilde Van Boxstael
  • Livio Luyten
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Wim Hoste
  • Wim Lewi

ResearchPool Subscriptions

Get the most out of your insights

Get in touch